207 related articles for article (PubMed ID: 28521118)
1. Automated cassette-based production of high specific activity [
Li M; Zhang X; Quinn TP; Lee D; Liu D; Kunkel F; Zimmerman BE; McAlister D; Olewein K; Menda Y; Mirzadeh S; Copping R; Johnson FL; Schultz MK
Appl Radiat Isot; 2017 Sep; 127():52-60. PubMed ID: 28521118
[TBL] [Abstract][Full Text] [Related]
2.
Li M; Sagastume EA; Lee D; McAlister D; DeGraffenreid AJ; Olewine KR; Graves S; Copping R; Mirzadeh S; Zimmerman BE; Larsen RH; Johnson FL; Schultz MK
Curr Med Chem; 2020; 27(41):7003-7031. PubMed ID: 32720598
[TBL] [Abstract][Full Text] [Related]
3. Structural modifications toward improved lead-203/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors.
Lee D; Li M; Liu D; Baumhover NJ; Sagastume EA; Marks BM; Rastogi P; Pigge FC; Menda Y; Johnson FL; Schultz MK
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1147-1162. PubMed ID: 37955792
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of
Banerjee SR; Minn I; Kumar V; Josefsson A; Lisok A; Brummet M; Chen J; Kiess AP; Baidoo K; Brayton C; Mease RC; Brechbiel M; Sgouros G; Hobbs RF; Pomper MG
J Nucl Med; 2020 Jan; 61(1):80-88. PubMed ID: 31253744
[TBL] [Abstract][Full Text] [Related]
5. Production and in vivo imaging of (203)Pb as a surrogate isotope for in vivo (212)Pb internal absorbed dose studies.
Máthé D; Szigeti K; Hegedűs N; Horváth I; Veres DS; Kovács B; Szűcs Z
Appl Radiat Isot; 2016 Aug; 114():1-6. PubMed ID: 27156049
[TBL] [Abstract][Full Text] [Related]
6. Purification of cyclotron-produced 203Pb for labeling Herceptin.
Garmestani K; Milenic DE; Brady ED; Plascjak PS; Brechbiel MW
Nucl Med Biol; 2005 Apr; 32(3):301-5. PubMed ID: 15820766
[TBL] [Abstract][Full Text] [Related]
7. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
[TBL] [Abstract][Full Text] [Related]
8. Novel, cysteine-modified chelation strategy for the incorporation of [M(I)(CO)(3)](+) (M = Re, (99m)Tc) in an α-MSH peptide.
Jiang H; Kasten BB; Liu H; Qi S; Liu Y; Tian M; Barnes CL; Zhang H; Cheng Z; Benny PD
Bioconjug Chem; 2012 Nov; 23(11):2300-12. PubMed ID: 23110503
[TBL] [Abstract][Full Text] [Related]
9. A Metabolically Stable Boron-Derived Tyrosine Serves as a Theranostic Agent for Positron Emission Tomography Guided Boron Neutron Capture Therapy.
Li J; Shi Y; Zhang Z; Liu H; Lang L; Liu T; Chen X; Liu Z
Bioconjug Chem; 2019 Nov; 30(11):2870-2878. PubMed ID: 31593447
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the radiosynthesis of [
Ghai A; Singh B; Li M; Daniels TA; Coelho R; Orcutt K; Watkins GL; Norenberg JP; Cvet D; Schultz MK
Appl Radiat Isot; 2018 Oct; 140():333-341. PubMed ID: 30138815
[TBL] [Abstract][Full Text] [Related]
11. Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111)In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues.
Cheng Z; Chen J; Miao Y; Owen NK; Quinn TP; Jurisson SS
J Med Chem; 2002 Jul; 45(14):3048-56. PubMed ID: 12086490
[TBL] [Abstract][Full Text] [Related]
12. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of no-carrier added
Sarkar K; Lahiri S; Sen K
Appl Radiat Isot; 2017 Mar; 121():16-21. PubMed ID: 28013152
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, characterization, and labeling with 99mTc/188Re of peptide conjugates containing a dithia-bisphosphine chelating agent.
Gali H; Hoffman TJ; Sieckman GL; Owen NK; Katti KV; Volkert WA
Bioconjug Chem; 2001; 12(3):354-63. PubMed ID: 11353532
[TBL] [Abstract][Full Text] [Related]
15. 3p-C-NETA: A versatile and effective chelator for development of Al
Ahenkorah S; Murce E; Cawthorne C; Ketchemen JP; Deroose CM; Cardinaels T; Seimbille Y; Fonge H; Gsell W; Bormans G; Ooms M; Cleeren F
Theranostics; 2022; 12(13):5971-5985. PubMed ID: 35966589
[No Abstract] [Full Text] [Related]
16. Specific Cytotoxicity of Targeted
Pankratov AA; Nemtsova ER; Plyutinskaya AD; Vorontsova MS; Chuvilin DY; Egorova BV; Kokov KV; Deev SM; Lebedenko EN; Proshkina GM; Shul'ga AA; Golovachenko VA; Shegai PV; Kaprin AD
Bull Exp Biol Med; 2021 Sep; 171(5):627-632. PubMed ID: 34626281
[TBL] [Abstract][Full Text] [Related]
17. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical.
Lopez-Rodriguez V; Gaspar-Carcamo RE; Pedraza-Lopez M; Rojas-Calderon EL; Arteaga de Murphy C; Ferro-Flores G; Avila-Rodriguez MA
Nucl Med Biol; 2015 Feb; 42(2):109-14. PubMed ID: 25316595
[TBL] [Abstract][Full Text] [Related]
18. Metal-Free Cycloaddition Chemistry Driven Pretargeted Radioimmunotherapy Using α-Particle Radiation.
Shah MA; Zhang X; Rossin R; Robillard MS; Fisher DR; Bueltmann T; Hoeben FJM; Quinn TP
Bioconjug Chem; 2017 Dec; 28(12):3007-3015. PubMed ID: 29129050
[TBL] [Abstract][Full Text] [Related]
19. Radiopharmaceutical development of radiolabelled peptides.
Fani M; Maecke HR
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S11-30. PubMed ID: 22388624
[TBL] [Abstract][Full Text] [Related]
20. 203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection.
Miao Y; Figueroa SD; Fisher DR; Moore HA; Testa RF; Hoffman TJ; Quinn TP
J Nucl Med; 2008 May; 49(5):823-9. PubMed ID: 18413404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
